liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Evaluation of Serum Substance P Level and Tissue Distribution of NK-1 Receptor in Papillary Thyroid Cancer
Mashhad Univ Med Sci, Iran.
Mashhad Univ Med Sci, Iran.
Mashhad Univ Med Sci, Iran.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Molecular Medicine and Virology. Linköping University, Faculty of Medicine and Health Sciences.
Show others and affiliations
2021 (English)In: Middle East Journal of Cancer, ISSN 2008-6709, E-ISSN 2008-6687, Vol. 12, no 4, p. 491-498Article in journal (Refereed) Published
Abstract [en]

Background: Papillary thyroid carcinoma (PTC) is the most prevalent malignancy of the endocrine system. This study was aimed at evaluating the serum substance P (SP) levels, the tissue distribution of Neurokinin-1 receptors (NK1-R), and their possible diagnostic value in PTC. Method: The present case-control study included 31 healthy volunteers and 31 cases (age range: 25-64, 40.26 +/- 12.77), who were primarily diagnosed with PTC and were candidates for total thyroidectomy. Pre-operative serum level of SP was measured using a commercial ELISA kit. The tissue distribution of NK1-R was assessed immunohistochemically. Results: The serum level of SP in the patient group was higher than the healthy volunteers (P = 0.005). Besides, the expression of NK1-R was higher in tumoral tissues compared with their normal surroundings (P = 0.005). However, we observed no significant correlation between either SP level or NK1-R expression and the disease stage or lymph node involvement. Conclusion: SP level and NK1-R expression were upregulated in PTC patients, showing the involvement of SP/NK1R complex in PTC pathophysiology. Nonetheless, proposing SP/NK1R as a diagnostic factor requires further studies because we found no correlation between SP/NK1R and clinical stage or lymph node involvement.

Place, publisher, year, edition, pages
SHIRAZ UNIV MEDICAL SCIENCES , 2021. Vol. 12, no 4, p. 491-498
Keywords [en]
Thyroid carcinoma; Substance P (SP); NK1R; Tachykinin; Cancer
National Category
Clinical Laboratory Medicine
Identifiers
URN: urn:nbn:se:liu:diva-181698DOI: 10.30476/mejc.2020.85658.1297ISI: 000721496400005OAI: oai:DiVA.org:liu-181698DiVA, id: diva2:1618013
Note

Funding Agencies|Research Council of Mashhad University of Medical Sciences [910817]

Available from: 2021-12-08 Created: 2021-12-08 Last updated: 2021-12-08

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Search in DiVA

By author/editor
Boroumand, Nadia
By organisation
Division of Molecular Medicine and VirologyFaculty of Medicine and Health Sciences
In the same journal
Middle East Journal of Cancer
Clinical Laboratory Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 91 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf